Megestrol acetate v tamoxifen in advanced breast cancer

Correlation of hormone receptors and response

David S Ettinger, J. Allegra, J. R. Bertino, P. Bonomi, H. Browder, P. Byrne, J. Carpenter, R. Catalano, R. Creech, B. Dana, H. Durivage, L. Einhorn, F. A. Greco, E. Greenwald, I. Henderson, F. Holmes, J. Keller, B. Kinzbrunner, M. Losada, S. Luedke & 7 others H. Muss, N. Nimeh, G. Wampler, N. Weinreb, J. Weisberg, R. Wheeler, P. H. Wiernik

Research output: Contribution to journalArticle

Abstract

This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35% with megestrol acetate and 42% with tamoxifen. Twenty-three percent ( 7 30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22% ( 6 27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalSeminars in Oncology
Volume13
Issue number4 SUPPL. 4
StatePublished - 1986
Externally publishedYes

Fingerprint

Megestrol Acetate
Tamoxifen
Hormones
Breast Neoplasms
Progesterone Receptors
Estrogen Receptors
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Ettinger, D. S., Allegra, J., Bertino, J. R., Bonomi, P., Browder, H., Byrne, P., ... Wiernik, P. H. (1986). Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptors and response. Seminars in Oncology, 13(4 SUPPL. 4), 9-14.

Megestrol acetate v tamoxifen in advanced breast cancer : Correlation of hormone receptors and response. / Ettinger, David S; Allegra, J.; Bertino, J. R.; Bonomi, P.; Browder, H.; Byrne, P.; Carpenter, J.; Catalano, R.; Creech, R.; Dana, B.; Durivage, H.; Einhorn, L.; Greco, F. A.; Greenwald, E.; Henderson, I.; Holmes, F.; Keller, J.; Kinzbrunner, B.; Losada, M.; Luedke, S.; Muss, H.; Nimeh, N.; Wampler, G.; Weinreb, N.; Weisberg, J.; Wheeler, R.; Wiernik, P. H.

In: Seminars in Oncology, Vol. 13, No. 4 SUPPL. 4, 1986, p. 9-14.

Research output: Contribution to journalArticle

Ettinger, DS, Allegra, J, Bertino, JR, Bonomi, P, Browder, H, Byrne, P, Carpenter, J, Catalano, R, Creech, R, Dana, B, Durivage, H, Einhorn, L, Greco, FA, Greenwald, E, Henderson, I, Holmes, F, Keller, J, Kinzbrunner, B, Losada, M, Luedke, S, Muss, H, Nimeh, N, Wampler, G, Weinreb, N, Weisberg, J, Wheeler, R & Wiernik, PH 1986, 'Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptors and response', Seminars in Oncology, vol. 13, no. 4 SUPPL. 4, pp. 9-14.
Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P et al. Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptors and response. Seminars in Oncology. 1986;13(4 SUPPL. 4):9-14.
Ettinger, David S ; Allegra, J. ; Bertino, J. R. ; Bonomi, P. ; Browder, H. ; Byrne, P. ; Carpenter, J. ; Catalano, R. ; Creech, R. ; Dana, B. ; Durivage, H. ; Einhorn, L. ; Greco, F. A. ; Greenwald, E. ; Henderson, I. ; Holmes, F. ; Keller, J. ; Kinzbrunner, B. ; Losada, M. ; Luedke, S. ; Muss, H. ; Nimeh, N. ; Wampler, G. ; Weinreb, N. ; Weisberg, J. ; Wheeler, R. ; Wiernik, P. H. / Megestrol acetate v tamoxifen in advanced breast cancer : Correlation of hormone receptors and response. In: Seminars in Oncology. 1986 ; Vol. 13, No. 4 SUPPL. 4. pp. 9-14.
@article{129b2899f15742c382f160c972ff3a68,
title = "Megestrol acetate v tamoxifen in advanced breast cancer: Correlation of hormone receptors and response",
abstract = "This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35{\%} with megestrol acetate and 42{\%} with tamoxifen. Twenty-three percent ( 7 30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22{\%} ( 6 27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.",
author = "Ettinger, {David S} and J. Allegra and Bertino, {J. R.} and P. Bonomi and H. Browder and P. Byrne and J. Carpenter and R. Catalano and R. Creech and B. Dana and H. Durivage and L. Einhorn and Greco, {F. A.} and E. Greenwald and I. Henderson and F. Holmes and J. Keller and B. Kinzbrunner and M. Losada and S. Luedke and H. Muss and N. Nimeh and G. Wampler and N. Weinreb and J. Weisberg and R. Wheeler and Wiernik, {P. H.}",
year = "1986",
language = "English (US)",
volume = "13",
pages = "9--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 4",

}

TY - JOUR

T1 - Megestrol acetate v tamoxifen in advanced breast cancer

T2 - Correlation of hormone receptors and response

AU - Ettinger, David S

AU - Allegra, J.

AU - Bertino, J. R.

AU - Bonomi, P.

AU - Browder, H.

AU - Byrne, P.

AU - Carpenter, J.

AU - Catalano, R.

AU - Creech, R.

AU - Dana, B.

AU - Durivage, H.

AU - Einhorn, L.

AU - Greco, F. A.

AU - Greenwald, E.

AU - Henderson, I.

AU - Holmes, F.

AU - Keller, J.

AU - Kinzbrunner, B.

AU - Losada, M.

AU - Luedke, S.

AU - Muss, H.

AU - Nimeh, N.

AU - Wampler, G.

AU - Weinreb, N.

AU - Weisberg, J.

AU - Wheeler, R.

AU - Wiernik, P. H.

PY - 1986

Y1 - 1986

N2 - This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35% with megestrol acetate and 42% with tamoxifen. Twenty-three percent ( 7 30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22% ( 6 27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.

AB - This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35% with megestrol acetate and 42% with tamoxifen. Twenty-three percent ( 7 30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22% ( 6 27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.

UR - http://www.scopus.com/inward/record.url?scp=0022901001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022901001&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 9

EP - 14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 4

ER -